Tough-to-treat tumors present big challenges and opportunities for big pharma oncology teams. These teams are spending big money bulking up pipelines with specialty drugs designed to replace prior generation therapies.
Novartis (NYSE:NVS) has been preparing for a reacceleration of patent expiration by bringing Signifor through clinic in hopes it will step in and win some of the market share that Sandostatin is posed to give up when it loses patent protection in 2014.
The Sandostatin cliff
Sandostatin is a drug that helps regulate the pituitary gland and reduce the symptoms associated with growth hormone producing tumors common in acromegaly, a rare and potentially life-threatening condition. The hard-to-diagnose condition takes as many as 12 years to diagnose following the first symptoms and just 6 of 100,000 people are diagnosed with it each year.
In most cases, acromegaly is caused by a non-cancerous pituitary tumor that produces growth hormone. Overproduction can also be caused by hypothalamic tumors and non-endocrine tumors -- although those causes are rarer.
The reason the disease is hard to diagnose is because symptoms are fairly common and include stomach pain, diarrhea, and flushing. Once diagnosed, the most common treatment of pituitary tumors is surgery.
But, in cases where surgery isn't possible -- and in many cases as part of pre- or post-therapy -- Novartis Sandostatin is prescribed. As a result, the drug generated $1.5 billion in sales during 2012, 5% more than it produced in 2011. That sales strength is continuing this year. Of the $2.7 billion Novartis generated in oncology sales during the third quarter, Sandostatin accounted for $401 million, up 7% from a year ago. Of those sales, $216 million were generated internationally. Worldwide, sales of Sandostatin total $1.17 billion in the first nine months, up 7% from last year.
Protecting the Sandostatin franchise
Given its blockbuster status, the stakes are high for Novartis to protect its Sandostatin franchise. The company hopes its drug Signifor, approved as a treatment for Cushing's disease last December, can win FDA approval for acromegaly before Sandostatin loses patent protection next June. The company is ushering the drug through phase 3 studies and plans to file for the indication soon.
Phase 3 results released in May show that Signifor offers promising results in treating acromegaly. In the study, 31% of patients on Signifor gained full control over their disease, compared to 19% of patients treated with Sandostatin. If Signifor does gain approval, it will offer Novartis patent protection until 2026 -- giving Novartis a long-term opportunity to maintain hundreds of millions in sales annually.
Competitive threats remain
Although there aren't many other treatments available, Pfizer (NYSE:PFE) has been marketing its Somavert as a treatment since winning FDA approval in 2003. In trials, those treated with 10, 15 or 20 mg/day of Somavert saw serum IGF-I levels -- a marker for growth hormone production -- normalize in 39%, 75% and 82% of patients, well above the 10% for those on placebo. Sales of the drug climbed 16% internationally and 8% in the United States during Q3 to $43 million and $13 million, respectively. That brought worldwide year to date sales to $159 million, up 11%.
But, a more disruptive treatment may be in the wings. Roche (NASDAQOTH: RHHBY) acquired the rights to a promising drug, Octreolin, from Chiasma earlier this year in a deal worth up to $595 million. Because Octreolin is dosed orally, Roche believes it can win significant share from Novartis and Pfizer's injectables. In phase 2 trials, Octreolin reduced growth hormone production by 80%, and the company expects results from phase 3 could come by year end. If Chiasma's drug is eventually approved, Roche's Genentech will leverage its large oncology sales force to pitch the drug in the U.S., putting significant pressure on both Novartis and Pfizer's sales force.
The Foolish final take
Novartis isn't alone in trying to reduce the risk to long standing blockbuster drugs from generics. And there is a risk Signifor won't win FDA approval for the indication prior to Sandostatin losing patent protection. But Signifor's current status as an approved drug for treating Cushing's does suggest the FDA is comfortable with the drug, and trial results seem to suggest Signifor outperforms Sandostatin, making for a compelling case. As a result, the bigger risk to Novartis may not be Signifor's approval for the indication, or Pfizer's ability to win share from Sandostatin, but instead the potential all-oral Octreolin being developed by Roche and Chiasma. That means you should pay close attention to Octreolin's upcoming phase 3 results.
Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC, an institutional research firm. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd also owns Gundalow Advisors, LLC, a high net worth advisory. Gundalow's clients do not own positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.